This week in therapeutics




Licensing status

Publication and contact information



Transient receptor potential A1 (TRPA1)

Mouse and cell culture studies suggest inhibiting TRPA1 could help prevent chemotherapy-induced sensory neuropathy. In mice that have received Velcade bortezomib or oxaliplatin, TRPA1 antagonists transiently decreased hyperalgesia and allodynia compared with vehicle. In mice, TRPA1 antagonists given before and shortly after treatment with Velcade or oxaliplatin prevented hyperalgesia and allodynia. Next steps could include testing clinical-stage TRPA1 antagonists in additional animal models of chemotherapy-induced neuropathy.
Glenmark Pharmaceuticals Ltd.'s TRPA1 antagonist GRC 17536 is in Phase I testing to treat pain.
Takeda Pharmaceutical Co. Ltd.'s Millennium Pharmaceuticals Inc. unit and Johnson & Johnson market Velcade, a small molecule dipeptide boronic acid proteasome inhibitor, to treat multiple myeloma (MM) and mantle cell lymphoma (MCL).
Oxaliplatin is a generic chemotherapeutic.

SciBX 6(13); doi:10.1038/scibx.2013.318
Published online April 4, 2013

Patent and licensing status unavailable

Trevisan, G. et al. Cancer Res.;
published online March 11, 2013;
Contact: Pierangelo Geppetti, University of Florence, Florence, Italy